ClinicalTrials.govpublic full text
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
multiple myeloma, multiple myeloma, etentamig, abbv-383, cancer, daratumumab, lenalidomide, dexamethasone, carfilzomib, abbv-2001, iberdomide, mezigdomide, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 992559
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.